- Home
- INCY vs PFG Comparison
INCY vs PFG Comparison
Compare INCY & PFG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INCY
- PFG
- Stock Information
- Founded
- INCY 1991
- PFG 1879
- Country
- INCY United States
- PFG United States
- Employees
- INCY N/A
- PFG N/A
- Industry
- INCY Biotechnology: Commercial Physical & Biological Resarch
- PFG Specialty Insurers
- Sector
- INCY Health Care
- PFG Finance
- Exchange
- INCY Nasdaq
- PFG Nasdaq
- Market Cap
- INCY 17.0B
- PFG 17.8B
- IPO Year
- INCY 1993
- PFG N/A
- Fundamental
- Price
- INCY $105.96
- PFG $85.29
- Analyst Decision
- INCY Buy
- PFG Hold
- Analyst Count
- INCY 19
- PFG 10
- Target Price
- INCY $89.19
- PFG $88.40
- AVG Volume (30 Days)
- INCY 2.9M
- PFG 1.3M
- Earning Date
- INCY 10-28-2025
- PFG 10-27-2025
- Dividend Yield
- INCY N/A
- PFG 3.70%
- EPS Growth
- INCY 3878.02
- PFG N/A
- EPS
- INCY 5.90
- PFG 6.91
- Revenue
- INCY $4,813,105,000.00
- PFG $15,800,800,000.00
- Revenue This Year
- INCY $19.33
- PFG $0.01
- Revenue Next Year
- INCY $10.47
- PFG $7.59
- P/E Ratio
- INCY $18.34
- PFG $12.34
- Revenue Growth
- INCY 18.09
- PFG 12.33
- 52 Week Low
- INCY $53.56
- PFG $68.39
- 52 Week High
- INCY $109.28
- PFG $90.31
- Technical
- Relative Strength Index (RSI)
- INCY 73.65
- PFG 65.25
- Support Level
- INCY $91.16
- PFG $80.80
- Resistance Level
- INCY $109.28
- PFG $83.30
- Average True Range (ATR)
- INCY 4.54
- PFG 1.65
- MACD
- INCY 0.92
- PFG 0.41
- Stochastic Oscillator
- INCY 86.44
- PFG 89.19
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About PFG Principal Financial Group Inc
Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.